Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504320 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Febuxostat XR Relative Bioavailability Study
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT02504320: Completed Phase 1 study, sponsored by Takeda.
NCT02504320 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 78 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02504320, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.
Primary Outcome
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Interventions
- DRUG Febuxostat XR 80 mg Capsule F1
- DRUG Febuxostat XR 80 mg Capsule F2
- DRUG Febuxostat XR 80 mg Capsule F3
- DRUG Febuxostat XR 80 mg Capsule F4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2015-08 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
What the finished NCT02504320 record still lists
NCT02504320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 4 interventions - of which Febuxostat XR 80 mg Capsule F1 is the first listed.
NCT02504320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02504320 about?
NCT02504320 is a clinical study titled "Phase 1, Febuxostat XR Relative Bioavailability Study". This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.
What is the current status of trial NCT02504320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2015-08. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02504320?
The interventions under investigation include: Febuxostat XR 80 mg Capsule F1 (DRUG), Febuxostat XR 80 mg Capsule F2 (DRUG), Febuxostat XR 80 mg Capsule F3 (DRUG), Febuxostat XR 80 mg Capsule F4 (DRUG).
Who is sponsoring clinical trial NCT02504320?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02504320's enrollment target sits among peer trials
78 697th of 2000 higher than 1,298 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia